Naples Laser & Skin

Components	Semaglutide Glycine
Semaglutide class	Synthetic GLP-1 receptor agonist — 31-amino-acid fatty-acid modified peptide analog
Semaglutide MW	≈ 4,113.6 g/mol
Glycine class	Non-essential amino acid — naturally occurring in the body; used here as a stabilizing excipient and physiologically compatible carrier
Form	2 mL multi-dose vial 4 mL multi-dose vial Subcutaneous injection Compounded formulation; vial size accommodates varying dose escalation schedules
Half-life	≈ 7 days (semaglutide — supports once-weekly dosing)
Rx status	Prescription only — treatment appropriateness determined by licensed provider based on individual health history and goals
Origin	Semaglutide developed by Novo Nordisk; engineered from native GLP-1 with fatty acid modification enabling albumin-binding and extended circulation

HOW IT WORKS

Semaglutide is a GLP-1 receptor agonist that works through pathways involved in appetite regulation and food intake signaling in the brain and gut, supporting medically supervised weight management. Glycine is a naturally occurring non-essential amino acid found throughout the body — involved in protein synthesis, connective tissue support, and metabolic function. In this compounded formulation, glycine serves as a stabilizing excipient and physiologically compatible carrier. Your provider will determine whether this treatment is clinically appropriate based on your health history and individual goals.

WHAT TO EXPECT

Medically supervised weight management programs
Metabolic health and obesity medicine practices
Compounding pharmacies (US-formulated)
Provider-supervised care plans with ongoing clinical monitoring

BEFORE YOU START

A compounded formulation pairing a synthetic GLP-1 analog with glycine — an endogenous amino acid used here as a stabilizing carrier, distinguishing it from B12-combination or single-agent semaglutide preparations. Available in both 2 mL and 4 mL multi-dose vials to accommodate varying dose escalation schedules. Semaglutide's extended half-life supports once-weekly subcutaneous dosing. All use requires a valid prescription and licensed provider oversight, with treatment appropriateness determined by individual health history and goals.